Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial

BackgroundRadiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non-small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor control is not achieved due to radioresistance. Concurrent inhibition of epidermal growth factor recep...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Hanne Marte Nymoen, Tine Norman Alver, Henrik Horndalsveen, Hanne Astrid Eide, Maria Moksnes Bjaanæs, Odd Terje Brustugun, Bjørn Henning Grønberg, Vilde Drageset Haakensen, Åslaug Helland
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	non-small cell lung cancer radioresistance EGFR-inhibitor erlotinib adverse events toxicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1412716/full

Similar Items

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
by: Christian Wilhelm Langberg, et al.
Published: (2023-07-01)

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
by: Saima Jamil Farooqi, et al.
Published: (2024-12-01)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
by: Henrik Horndalsveen, et al.
Published: (2023-03-01)

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
by: Henrik Horndalsveen, et al.
Published: (2025-10-01)

Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
by: Johanne Elise Nyen, et al.
Published: (2025-03-01)

Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
by: Johanne Elise Nyen, et al.
Published: (2025-02-01)

Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway
by: Steinar Solberg, et al.
Published: (2025-10-01)

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
by: Janna Berg, et al.
Published: (2021-05-01)

Distribution and characteristics of malignant tumours by lung lobe
by: Yngvar Nilssen, et al.
Published: (2024-03-01)

Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib
by: Azadeh Abravan, et al.
Published: (2017-06-01)

Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer.
by: Oddmund Nordgård, et al.
Published: (2013-01-01)

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
by: Åsa Kristina Öjlert, et al.
Published: (2019-05-01)

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
by: Ane Kongsgaard, et al.
Published: (2016-06-01)

Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma
by: Odd Terje Brustugun, et al.
Published: (2025-07-01)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
by: Ane Kongsgaard, et al.
Published: (2013-11-01)

TP53 mutation spectrum in smokers and never smoking lung cancer patients
by: Ann Rita Halvorsen, et al.
Published: (2016-05-01)

Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
by: Maria Moksnes Bjaanæs, et al.
Published: (2021-04-01)

Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016
by: Yngvar Nilssen, et al.
Published: (2020-05-01)

N‐glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
by: Thilde Terkelsen, et al.
Published: (2018-06-01)

Evaluation of sex inequity in lung-cancer-specific survival
by: Dan Lærum, et al.
Published: (2024-05-01)

The Serbian Church Slavonic text of the Martyrion of Dorotheos of Alexandria
by: Terje Helland
Published: (2006-01-01)

Targeting lung cancer through inhibition of checkpoint kinases
by: Randi Gussgard Syljuåsen, et al.
Published: (2015-02-01)

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
by: Sólrún Melkorka Maggadóttir, et al.
Published: (2022-11-01)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
by: Kathleen E. Spitz, MD, MBA, et al.
Published: (2022-07-01)

COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
by: Tom Børge Johannesen, et al.
Published: (2021-03-01)

Innovasjon i kulturskolen? Fem rektorers oppfatninger
by: Odd Christian Hagen, et al.
Published: (2025-02-01)

Erlotinib-induced dry eye
by: Rashmita Ravisankar, et al.
Published: (2023-01-01)

Monitorering og reversering av nevromuskulær blokade ved generell anestesi – en tverrsnittsundersøkelse av anestesipersonells praksis og vurderinger
by: Sigrunn Drageset, et al.
Published: (2023-05-01)

Guided Internet-based cognitive behavioral therapy for mild and moderate depression: A benchmarking study
by: Hanne Jakobsen, et al.
Published: (2017-03-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012-06-01)

Scalp acneiform rash caused by erlotinib: a case report
by: Zhang Qian, Zhang Xin, Wang Qian, Zhou Xiyuan, Zhang Lixia
Published: (2023-07-01)

Development and Application of an HPLC Method for Erlotinib Protein Binding Studies
by: Soheila Bolandnazar, et al.
Published: (2013-08-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy
by: Karen Olthoff, et al.
Published: (2024-11-01)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
by: Atakan Topcu, et al.
Published: (2022-10-01)

Dramatic Improvement of Severe Cicatricial Ectropion after Discontinuing Long-Term Erlotinib Therapy in a Patient with Lung Cancer
by: Mehmet Serhat Mangan
Published: (2022-02-01)

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation
by: Yujing Wang, et al.
Published: (2024-12-01)

Fallgruver i følgeforskning
by: Odd Einar Olsen, et al.
Published: (2002-05-01)